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REPORTING STANDARDS
The use of vena caval filters has increased signif-
icantly since the introduction of percutaneous place-
ment techniques and the development of reduced-
profile devices. The literature contains hundreds of
reports of immediate and long-term outcomes for
patients in whom these devices have been placed,
but the reports do not use consistent standards, def-
initions, or techniques, making it difficult to com-
pare outcomes and determine the relative efficacy
and safety of the available devices.1-3
Successful deployment of a vena caval filter fun-
damentally requires a patent filter, properly posi-
tioned within the vena cava in a manner that pro-
tects against pulmonary embolism. With this
premise, reporting standards have been developed to
assess caval filter placement, function, and other out-
come parameters. They are applicable to all vena
caval filters, regardless of other reportable aspects:
basic design, manufacturer, the specialty of the clin-
ician placing the device, the indications for which it
was placed, and whether it was intended for perma-
nent or temporary use. These data should be evalu-
ated with rigorous statistical methods to allow unbi-
ased comparisons that should lead to improved out-
comes for patients. Extensive literature citations
have been included, either to highlight the signifi-
cance of each standard or to provide examples of
typical reports.
PATIENT ASSESSMENT
General patient information, including age, sex,
underlying disease and level of severity, and current use
of anticoagulation (type and level), should be noted.4,5
Patient informed consent and institutional review
board approval, when appropriate, should be docu-
mented. Because outcomes are related to the underly-
ing venous disorder, the presence or absence of venous
thromboembolism (pulmonary embolism [PE], deep
venous thrombosis [DVT], or both) should be
described, along with the extent of DVT involvement
for correlation with subsequent status of the limb. PE
should be objectively documented with available imag-
ing studies, including radionuclide ventilation/perfu-
sion scans using the Prospective Investigation on
Pulmonary Embolism Diagnosis (PIOPED) criteria,6
pulmonary angiography, echocardiography, contrast-
enhanced spiral computed tomography (CT), or
gadolinium-enhanced magnetic resonance (MR)
angiography.7-12 The presence of DVT should be doc-
umented by means of contrast venography, duplex
ultrasound scanning, CT, or MR venography.13-15 The
proximal extent of thrombus and the percent of great-
est luminal narrowing should be identified (Table I).
The patient’s risk factors for venous thrombosis
should be identified (Table II). This is especially
important when the filter is placed for prophylaxis in
the absence of thromboembolism.16-20
The indications for filter placement should be
identified (Table III).21-25 Multiple indications may
be present, but only the primary one should be used
for group analyses.3,26 Normal and abnormal factors
related to successful filter placement should be
described. These include: (1) the transverse caval
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diameter at the level of desired placement, corrected
for magnification; (2) caval anomalies, such as dupli-
cation or renal vein anomalies; (3) spinal deformi-
ties; and (4) the patency of the planned access site
(graded according to Table I).
DEVICE ASSESSMENT
The manufacturer and type of filter should be
recorded, as should the specific information con-
cerning the delivery system, such as the size of the
introducer system and use of a guidewire. The rea-
son for device selection should be noted (Table IV).
The intended duration of placement, either perma-
nent, temporary (requiring removal), or optional
(may be removed) should be indicated. 
PROCEDURAL ASSESSMENT 
The training background and specialty of the
physician placing the filter (such as interventional
radiologist, surgeon, interventional cardiologist, or
pulmonologist) should be identified, and the level of
experience of the physician should be characterized
as either trainee or staff. The timing of the procedure
should be classified as elective, urgent (within 24
hours of decision), or emergent (as soon as possible).
The location in which the procedure was con-
ducted (such as the operating room, radiology suite,
cardiac catheterization laboratory, bedside, or other)
should be identified.27-30 Any anesthesia other than
local should be indicated. 
The method by which the vena cava was evalu-
ated before placement of the device, ie, contrast
venography or intravascular ultrasound scanning,
should be provided.31-34 When venography is
used, the type of contrast and the degree and
method of correcting for magnification should be
included.35 Identification of the renal veins should
be reported.
The site of insertion should be identified by
name and location, such as left or right femoral or
jugular vein, an upper-extremity vein, the external
jugular vein, or by direct vena caval access. This is
important because the route of insertion has been
shown to affect performance in some cases.36-40 The
method of access should be described as being either
percutaneous or venotomy. If ultrasound scanning
guidance was used to identify the vessel, this should
also be reported. The intended site for deployment
should be recorded as infrarenal or suprarenal vena
cava, iliac vein, or the superior vena cava.41
PLACEMENT PROBLEMS
The characteristic steps of successful placement
are listed in Table V and should be referred to when
reporting placement problems. Problems should be
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Table I. Staging deep venous thrombosis
Extent of thrombus Grading of occlusion
Calf
Popliteal
Femoral 0 = Clear
1 = Partial occlusion
Iliac 2 = 0ccluded
Vena cava (inferior or superior)
Axillary/subclavian
Table III. Categorical indications for filter placement
1. Contraindication to anticoagulation (absolute or relative)
2. Complication of anticoagulation
a. Failure: objectively documented extension of existing 
deep venous thrombosis or new deep venous thrombosis 
or pulmonary embolism while therapeutically anticoagu-
lated
b. Hemorrhage: major or minor
c. Thrombocytopenia
d. Skin necrosis
e. Drug reaction
f. Evidence/probability of poor compliance
3. Prophylaxis: no thromboembolic disease90
4. Prophylaxis with thromboembolism in addition to anticoag-
ulation
5. Failure of previous device to prevent pulmonary embolism; 
central extension of thrombus through an existing filter or 
recurrent pulmonary embolism
6. In association with another procedure: thrombectomy, 
embolectomy, lytic therapy91-94
Table II. Classification of risk factors for throm-
boembolism
Factors
History of deep venous thrombosis
Immobilization
Postoperative status
Age
Malignancy and tissue type
Cardiac disease
Limb trauma
Prothrombotic state
Hormonal therapy
Pregnancy and postpartum
Obesity
Based on Porter JM, Moneta G, and International Consensus
Committee on Chronic Venous Disease. J Vasc Surg 1995;21:
635-45.
identified by and, in larger series, stratified by these
levels or steps and whether clinical sequelae devel-
oped as a result.
TECHNICAL SUCCESS/FAILURE
Technical success requires proper placement of
the filter. Each filter placement that is attempted
should be included in the total number of filter
placements reported, following the intent-to-treat
rule. Failures occur when the filter cannot be placed
as intended and a second attempt is made with a dif-
ferent filter.42-47
Procedural complications are not the same as
technical failures, but both should be reported.
Insertion site thrombosis or hemorrhage, infection
or the development of an arteriovenous fistula, or
positioning that requires placing an additional filter
or correcting the placement of an existing filter are
considered to be complications and should be identi-
fied as such.39,48,49 Insertion site thrombosis should
be graded as being either occlusive or non-occlusive,
and the method of diagnosis should be reported.50-52
Complications that require additional procedures,
prolong hospitalization, or result in death are consid-
ered to be major. Events that occur within 24 hours
are considered to be early, as compared with those
occurring after 24 hours.
FOLLOW-UP ASSESSMENT
Patients with permanently implanted devices
deserve routine follow-up.53-58 When this follow-up
is reported, the number of patients observed should
be compared with the total number of filters placed
at each institution during the period of the report.
Censored patients should be indicated as having been
lost to follow-up or being dead. The cause of death
and method of ascertainment should be identified.
The time between filter placement and follow-up
should be given as a mean with the standard devia-
tion and median, but in an intermediate or long-term
study, success rates should be reported with classic
life table or Kaplan-Meier plots.59 Clinical success is
defined as a technical success without subsequent
pulmonary embolism, significant filter migration or
malpositioning, symptomatic caval thrombosis, or
other complication requiring removal or invasive
intervention.
The preferred method for following up with
patients is by clinical examination and objective test-
ing. The clinical examination should include venous
duplex examination of the lower extremities for
recurrent DVT, chronic venous insufficiency, or
both.50,52,60-62 Edema, other post-thrombotic skin
changes or ulceration, the current use of anticoagu-
lants,63,64 any complications resulting in discontinu-
ation of anticoagulant therapy, and the occurrence
of suspected or proven PE should be reported.
When PE is reported, the method of diagnosis and
treatment received should be included. Minimum
objective testing should include evaluation of the
stability and patency of the filter. Patency of the fil-
ter and vena cava should be determined by means of
vena cavography, ultrasound scanning, CT, or MR
scanning. The findings should be accompanied by
statements concerning the adequacy of the examina-
tion.65-70 The report should indicate whether there
was thrombus within the vena cava, its location, and
whether it was occlusive.
The stability of the filter can be documented by
means of orthogonal plain films. From these, the loca-
tion of the filter relative to its original position at place-
ment in both the horizontal and vertical dimensions
should be determined. Change in vertical position and
the direction (proximal vs. distal) can be measured and
documented.71-77 The diameter at the base of the fil-
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Table V. Criteria for successful placement
1. The delivery system was advanced to the intended place-
ment level
2. The filter was deployed and fixed at the intended position
a. No migration (> 20 mm) or embolization of the filter
b. No extravascular penetration of guidewire or device
3. The filter configuration was consistent with protection
from pulmonary embolism
a. Complete opening42
b. Adequate distribution of filtering mechanism 
(no additional device was placed)96
c. Alignment with the axis of the vena cava (eg, tilting; 
record degree)
Table IV. Justification for device selection
1. Device routinely available at the institution
a. Clinician preference
b. Clinical research study
c. Training
d. Cost
2. Specific choice
a. Diameter of the vena cava
b. Upper extremity access95
c. To be positioned above the renal vein
d. Short period of thromboembolic risk (temporary or 
optional)
e. Ease of deployment
f. Access vein problem (tortuosity, thrombosis, 
compression, etc)
g. Freedom from magnetic susceptibility artifact
ter should be measured. A reduction in diameter of the
cone-shaped filters may suggest caval stenosis or occlu-
sion, and expansion can be indicative of extracaval
extension of the anchoring devices; therefore, both
should be reported.78 More specific tests, such as CT
scans, cavography, intravascular ultrasound scans, or
MR studies may be indicated to document penetration
and/or impingement on an adjacent organ or caval
occlusion. Finally, any deformation of the filter, ie,
fracture or collapse, should be reported.79-85
Outcome data should be based on samples of
sufficient size to support clinical conclusions. Actual
numbers, not just percentages, should be included.
Many literature reports are based on small case series
or even case reports that make it difficult to deter-
mine the magnitude of the problem. Data should be
obtained from primary contacts, which are less sub-
ject to the bias found in chart reviews or telephone
contacts.
TEMPORARY AND OPTIONAL DEVICES
Currently, there are no approved temporary
(must be removed) or optional (may be removed)
vena caval filters in the United States. However, there
is great interest among many physicians in evaluating
the efficacy and safety of these devices.86-89 Clinical
studies are currently in progress, and we urge that
study results be reported according to these recom-
mendations to facilitate fair evaluation. Reports for
these devices should include all the information list-
ed herein and also those factors particular to these
devices (Table VI). 
CONCLUSION
These recommendations are based on current
practice patterns and are subject to change as our
knowledge improves, technology changes, and prac-
tice develops. However, adherence to these guide-
lines, which are summarized in Table VII, will allow
the combination of reports from multiple sites and
provide a better level of evidence on which to base
future recommendations.
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Table VI. Additional reporting criteria for tempo-
rary and optional filters
1. Description of the device, including the materials
2. Recommendation for duration of placement
3. Whether it was used in conjunction with another procedure
4. Whether it was removed and the length of time it was in 
place
5. Complications related to removal of the device, ie, inability 
to remove according to directions, infection, or trapped 
embolus within the filter, and its fate97
6. How complication was treated
7. Need for a permanent filter
Table VII. Summary of reporting standards and
level of recommendation
Highly
Required recommended Recommended
Patient assessment
Age 
Sex 
Underlying disease 
Anticoagulation use 
DVT (diagnosed) 
PE (diagnosed) 
Risk factors 
Indications for placement 
Filter placement
IVC transverse diameter 
IVC/RV abnormality 
Spinal deformity 
Access site patency 
Device assessment
Device identification 
Guidewire use 
Reason for selection 
Intended duration of 
placement
Procedural assessment
Physician specialty 
Physician training level 
Location of procedure 
Type anesthesia 
Method of IVC evaluation 
Insertion site 
Method of access 
Use of ultrasound 
scanning
Deployment site 
Technical success rate 
Clinical sequelae 
Follow-up assessment
% patients observed 
Patient status 
Cause of death 
Time to death or failure 
Venous duplex 
Postphlebitic symptoms 
Anticoagulation 
Complication of anti- 
coagulation
Suspected/proven PE 
Diagnosis of PE 
Treatment of PE 
Filter stability 
IVC patency 
Method of determining 
patency
Outcomes reported as raw 
numbers and %
Source of data 
DVT, Deep venous thrombosis; PE, pulmonary embolism; 
IVC, inferior vena cava; RV, renal vein.
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